Affectis Pharmaceuticals AG and Organon, the human healthcare business unit
of Akzo Nobel, have entered into a collaboration by which Affectis will apply
its pioneering target validation technology and its exclusive preclinical models
for the validation of Organon's gene targets involved in depression and anxiety.
Today, one of the major challenges in developing optimised drugs against affective
disorders is the limited availability of suitable preclinical models and sufficient
expertise in selecting promising targets and leads as well as their preclinical